



EDITORIAL

The *European Respiratory Review*: mature, expanding and targeting new challenges

Vincent Cottin*[#]

BUILDING ON SUCCESS

Readers of the *European Respiratory Review* (*ERR*) will be pleased to see that the first issue of 2013 continues the noble task of providing up-to-date knowledge in respiratory medicine, with diversified and high-quality scientific content. As incoming Chief Editor, new captain of the ship [1], it is my pleasure to note that this ship is healthy and proudly moving forward. With the tremendous momentum of our friend and colleague Professor Marc Humbert from the University of Paris (Paris, France), Chief Editor of the *ERR* for the past 4 yrs, and the outstanding work of the European Respiratory Society (ERS) Publications Office, the *ERR* has built on the previous success and has become a major platform for the publication of high-quality review articles [2]. Since the restructuring of the *ERR* in 2009, all published articles are peer reviewed [2]. A proportion of reviews published in the *ERR* are sponsored articles [2], with full transparency and the necessary analysis of demanding external reviewers and an independent editorial board, as for all published articles.

A landmark was achieved in July 2010, with the indexing of the *ERR* in Medline/PubMed, facilitating full visibility of content to the community. As all *ERR* articles are free to access from the first day of publication, authors are assured full and rapid dissemination of knowledge, as illustrated by the exponential increase in the number of visits to the *ERR* website (<http://err.ersjournals.com>) and the number of downloaded *ERR* articles worldwide [3]. As an illustration, the top 10 most read articles since November 2010 have totalled more than 76,458 full-text downloads [4–13]. Together, the recently launched ERS publications app, the *ERR* website optimised for smartphones and tablets, the social bookmarks for Twitter and Facebook, and the twitter feed @ERSpublications, contribute to increasing the visibility of *ERR* articles.

Part of the fleet of ERS publications [1, 14], the *ERR* provides quarterly updates on medicine, science and surgery for all respiratory medicine professionals, and will continue to be primarily focused on clinical respiratory medicine. In recent

years, the *ERR* has published a number of outstanding review articles on chronic obstructive pulmonary disease, asthma, pulmonary hypertension, venous thromboembolic disease, interstitial lung disease, tuberculosis and cancer. Indeed, in a world of ever growing knowledge, complexity and diversity of publications, summarising the most relevant and recent research findings, together with up-to-date clinical science, is required more than ever. The *ERR* will continue to publish state-of-the-art reviews (updates), focused review articles, editorials, correspondence and book reviews.

EXPANDING AND TARGETING NEW CHALLENGES

What then is changing in the *ERR* in 2013? The topics of invited reviews will be broadened progressively to better cover all aspects of respiratory medicine. The editorial board is pleased to welcome new international members, some with expertise in areas such as oncology, sleep medicine, infectious diseases, rehabilitation, intensive care medicine and systemic diseases; topics that have been slightly less represented in past years although they correspond to a significant part of professional activity for many chest physicians. The *ERR* also aims to publishing proceedings of high-quality scientific meetings including, but not limited to, those endorsed by the ERS, as well as reports and supporting documents of ERS task forces, which will be actively sought.

The format of articles published in the *ERR* is also evolving (table 1). In addition to regular reviews and updates, review

TABLE 1 Types of articles published in the *European Respiratory Review*

Reviews	Other formats
Reviews	Editorials
Updates (state-of-the art)	Letter to the editors
ERS Task Force	Correspondence
supporting documents	
Proceedings from respiratory medicine meetings	Images in respiratory medicine
Thematic review series	Book reviews
Clinical year in reviews	
Case-based educational reviews	
Cutting-edge mini reviews	

ERS: European Respiratory Society.

*Hospices Civils de Lyon, Hôpital Louis Pradel, Service de pneumologie – Centre de référence national des maladies pulmonaires rares et Centre de compétences de l'hypertension artérielle pulmonaire and [#]Université Claude Bernard Lyon 1, INRA, UMR754 INRA-Vetagrups EPHE IFR 128, Lyon, France.

CORRESPONDENCE: V. Cottin, Hôpital Louis Pradel, Service de Pneumologie, 28 Avenue Doyen Lepine, 69677 Lyon Cedex, France. E-mail: vincent.cottin@chu-lyon.fr

PROVENANCE: Submitted article, peer reviewed.

articles will now include Thematic review series, the first of which on "Topics in thoracic oncology" is published in the current issue [15]. Clinical year in review articles, three of which are published in this issue [16–18], are authored by respected speakers at the eponymous symposium during the 2012 annual ERS Congress, and focus on the most recent advances in clinical medicine. Cutting edge mini-reviews and Case-based educational reviews, based on a small number of real-life illustrative cases [19], will be published in future issues. A section of Images in respiratory medicine will be initiated, with eye-catching figures and a short educational comment.

Furthermore, the links between the *ERR* and the flagship publication, the *European Respiratory Journal (ERJ)*, will be tightened. The transfer of manuscript submissions from one journal to the other has already been made easier and faster, and the *ERR* editorial board will work closely with the *ERJ* Chief Editor Professor Marc Humbert and Professor Anh-Tuan Dinh-Xuan, now *ERJ* deputy editor, who are also members of the *ERR* editorial board [3, 14, 20]. Correspondence articles referring to previously published *ERR* articles and Letters to the editor, corresponding to very short reports or to highly-selected case studies that harbour educational excellence or particular relevance for diagnosis or management, now have distinct formats, in line with the *ERJ*.

Last but not least, one further objective of the *ERR*, which we hope will be reached during my 3 yr editorial mandate, will be to apply for indexing by ISI and obtain an impact factor, as a further step to pursue the ultimate goal of publishing the best review content in respiratory medicine in the *ERR*.

STATEMENT OF INTEREST

V. Cottin has received fees for speaking from Intermune, Boehringer Ingelheim and Actelion, and has participated as an investigator to clinical trials sponsored by Intermune, Boehringer Ingelheim and Actelion, and as member of a steering committee for a clinical trial sponsored by Boehringer Ingelheim.

REFERENCES

- 1 Dinh-Xuan AT, Brusasco V, Wedzicha JA, *et al.* ERS publications: the flagship and the fleet. *Eur Respir J* 2012; 40: 535–537.
- 2 Humbert M. Introducing the new *European Respiratory Review*. *Eur Respir J* 2009; 33: 466–467.
- 3 Humbert M. You say goodbye, and I say hello! *Eur Respir Rev* 2012; 21: 265–266.
- 4 O'Donnell DE, Laveneziana P. Physiology and consequences of lung hyperinflation in COPD. *Eur Respir Rev* 2006; 15: 61–67.
- 5 Wilson R. Treatment of COPD exacerbations: antibiotics. *Eur Respir Rev* 2005; 14: 32–38.
- 6 Burgel P-R. The role of small airways in obstructive airway diseases. *Eur Respir Rev* 2011; 20: 23–33.
- 7 Bourdin A, Burgel P-R, Chanez P, *et al.* Recent advances in COPD: pathophysiology, respiratory physiology and clinical aspects, including comorbidities. *Eur Respir Rev* 2009; 18: 198–212.
- 8 Oh CK, Geba GP, Molfini N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. *Eur Respir Rev* 2010; 19: 46–54.
- 9 Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. *Eur Respir Rev* 2011; 20: 156–174.
- 10 Booker R. Effective communication with the patient. *Eur Respir Rev* 2005; 14: 93–96.
- 11 Connell DW, Berry M, Cooke G, *et al.* Update on tuberculosis: TB in the early 21st century. *Eur Respir Rev* 2011; 20: 71–84.
- 12 Balsamo R, Lanata L, Egan CG. Muscoactive drugs. *Eur Respir Rev* 2010; 19: 127–133.
- 13 Schaad UB. Prevention of paediatric respiratory tract infections: emphasis on the role of OM-85. *Eur Respir Rev* 2005; 14: 74–77.
- 14 Humbert M. The ambition of the *European Respiratory Journal*. *Eur Respir J* 2013; 41: 1–2.
- 15 Girard N. Thymic epithelial tumours: from basic principles to individualised treatment strategies. *Eur Respir Rev* 2013; 22: 75–87.
- 16 Cottin V. Interstitial lung disease. *Eur Respir Rev* 2013; 22: 26–32.
- 17 Sculier JP. Nonsmall cell lung cancer. *Eur Respir Rev* 2013; 22: 33–36.
- 18 Peacock A. Pulmonary hypertension. *Eur Respir Rev* 2013; 22: 20–25.
- 19 Montani D, O'Callaghan DS, Jais X, *et al.* Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre. *Eur Respir Rev* 2009; 18: 272–290.
- 20 Dinh-Xuan AT, Brusasco V. The editors' farewell and confident look back to the future. *Eur Respir J* 2012; 40: 1309–1311.